top of page
Search
bilyanamartinphd

Ivermectin and COVID-19 are all Questions and Answers.

Updated: Dec 14, 2021

What is ivermectin?

Ivermectin is an anti-parasitic drug developed during the 1970s as a partnership between the Kitasato Institute in Japan and Merck & Co. The project was led by Satoshi Omura and William Campbell on each side, respectively. Given its broad spectrum against internal and external parasites that improved animal health and boosted productivity, ivermectin quickly became a blockbuster drug in the veterinary field.

During the 1970s, the world was waging war against river blindness, also known as onchocerciasis, a disease caused by the Onchocerca volvulus parasite in rural areas that crippled whole communities. Who had already achieved some success thanks to the involvement of the World Bank? But once ivermectin was commercialized, What noticed that Onchocerca cervicalis, the agent of onchocerciasis in horses, practically disappeared in areas where the new drug was used.





This lead to accelerated efforts to test ivermectin in humans that ended with the approval of the French regulatory authorities in the early 1980s and was followed by the unprecedented decision by Merck & Co. to donate as much ivermectin as needed for as long as needed to eradicate river blindness. This gave birth to the Mectizan donation program. This program has distributed more than 3 billion treatments over the last 30 years and has saved countless lives throughout this period. What later expanded the program to include Lymphatic filariasis, another debilitating disease caused by filarial worms.

Omura and Campbell were awarded the Nobel prize for physiology or medicine in 2015 for this discovery, an honor shared with Tu Youyou, the Chinese researcher responsible for discovering the antimalarial artemisinin.

What is ivermectin used for in humans?

Here we describe some of the approved uses around the world.

1. In the US, ivermectin is marketed at doses of up to 200 mcg/kg once a year for the following indications:

a. Strongyloides stercoralis, an intestinal parasite capable of causing severe systemic disease.

b. Onchocerciasis or river blindness


2. In Europe, ivermectin is also marketed against Lymphatic filariasis and scabies at single doses of up to 400 mcg/kg.


3. In Australia, three or more-200 mcg/kg doses within a month are recommended to treat severe crusted scabies.


Any other proven or potential uses?

Although not marketed for these indications, ivermectin has partial efficacy against other common intestinal parasites in humans, such as Ascaris lumbricoides and Trichuris trichura.

It is also sometimes used out of label against ectoparasites like head lice and Tunga penetrans, among many other internal or external parasites.

One promising line of work in which ISGlobal researchers have been deeply involved in using ivermectin at the population level to kill mosquitoes that feed on treated humans or animals and reduce malaria transmission.


Is ivermectin safe?


When used for the current indications, ivermectin is a very safe drug at the currently approved doses. To date, more than three billion treatments have been distributed in the context of the Mectizan Donation Program alone, with an excellent safety profile. Most adverse reactions are mild, transitory, and associated with parasite death rather than with the drug itself.

Ivermectin targets the glutamate-gated chloride channels that are only present in invertebrates. Mammals only express a similar channel that could cross-react with ivermectin (the GABA-gated chlorine channels). Still, these are only expressed in the central nervous system and are protected by the blood-brain barrier, a system of pumps that keeps potential toxics outside our nervous system. Despite that, Rebecca Chandlerdescribed a series of 28 cases with severe neurological adverse reactions after ivermectin treatment outside onchocerciasis endemic areas.

In individuals infected with a high burden (>30.000 mg/ml) of the parasite known as Loa loa, ivermectin treatment can lead to severe encephalopathy and death. This has prevented the administration of ivermectin in several central Africa countries, where the current test-and-not-treat strategy may allow for drug use.

There is no robust evidence to support the use of ivermectin in children under 15 kg of weight. There is no evidence to support the use of ivermectin during pregnancy.


Is ivermectin safe at higher doses than approved?


Guzzo et al. conducted a study with escalating doses of ivermectin. Some volunteers safely received doses of up to 2,000 mcg/kg, i.e., ten times the approved dose for onchocerciasis.


Although not described by Guzzo, persons receiving ivermectin at doses of 800 mcg/kg or above in other studies have sometimes described transient visual disturbances.

Smit et al. safely administered 600 mcg/kg daily for three days.

Does ivermectin have anti-viral properties?

Yes. Ivermectin has been proven to inhibit the replication of several RNA viruses such as:

Dengue

Zika

Yellow fever

West Nile

Chikungunya

Venezuelan equine encephalitis

Semliki Forest virus

Sindbis virus

Porcine reproductive and respiratory syndrome virus, and recently

SARS-CoV-2


Could ivermectin have a role in the treatment or prevention of COVID-19?


Perhaps, but the answer is not straightforward.

Who did the in vitro experiments by Caly et al. by adding ivermectin into a cellular culture infected with the virus on a petri dish? The concentrations shown to reduce the viral replication by 50% and 99% in these experiments were 2.8 and 5 microMolar, respectively.

To put this into perspective, the maximum concentration achieved in the blood after a single oral dose of 200 mcg/kg (the usual dose for river blindness) is 40 ng/ml. 2.8 microMolar is the equivalent of 2,450 ng/ml, i.e., 60-fold higher than the maximum concentration after usual doses or 10-fold the maximum concentration observed in the high-dose Guzzo study.


14 views0 comments

Comments


bottom of page